COAPT Trial - Renal dysfunction and cardiac outcomes in heart failure
Patients with heart failure (HF) and severe secondary mitral regurgitation (MR) frequently also suffer from baseline renal disease (RD). Renal function is further impaired by HF and MR, often accelerating progression to end-stage renal disease (ESRD), necessitating a form of renal replacement therapy (RRT).
For patients with MR deemed too high-risk for surgery, the transcatheter mitral valve repair procedure MitraClipTM (Abbott, California, USA) has been shown to offer an alternative form of management of MR.
In the COAPT trial, investigators wanted to see if renal outcomes could be impacted by the use of this approach to MR management.
Learn more at cardiology-update.com
Watch video COAPT Trial - Renal dysfunction and cardiac outcomes in heart failure online without registration, duration hours minute second in high quality. This video was added by user Cardiology Update 12 June 2022, don't forget to share it with your friends and acquaintances, it has been viewed on our site 5 once and liked it lik people.